Lentiviral vector-mediated transduction of adult neural stem/progenitor cells isolated from the temporal tissues of epileptic patients

Document Type: Original Article


1 Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

2 Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran

3 Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Department of Neurosurgery, Westfälische Wilhelms-Universität, Münster, Germany

6 Epilepsy Research Center, Department of Neurology and Institute for Translational Neurology, Westfälische Wilhelms-Universität Münster, Münster, Germany

7 Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

8 Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): Neural stem/progenitor cells (NS/PCs) hold a great potential for delivery of therapeutic agents into the injured regions of the brain. Efficient gene delivery using NS/PCs may correct a genetic defect, produce therapeutic proteins or neurotransmitters, and modulate enzyme activation. Here, we investigated the efficiency of a recombinant lentivirus vector expressing green fluorescent protein (GFP) for genetic engineering of human NS/PCs obtained during brain surgery on patients with medically intractable epilepsy.
Materials and Methods: NS/PCs were isolated from human epileptic neocortical tissues. Three plasmids (pCDH, psPAX2, pMD2.G) were used to make the virus. To produce the recombinant viruses, vectors were transmitted simultaneously into HEk-293T cells. The lentiviral particles were then used to transduce human NS/PCs.
Results: Our in vitro study revealed that lentivirus vector expressing GFP efficiently transduced about 80% of human NS/PCs. The expression of GFP was assessed as early as 3 days following exposure and remained persistent for at least 4 weeks.
Conclusion: Lentiviral vectors can mediate stable, long-term expression of GFP in human NS/PCs obtained from epileptic neocortical tissues. This suggests lentiviral vectors as a potential useful tool in human NS/PCs-based gene therapy for neurological disorders, such as epilepsy.


1. Engel J. What can we do for people with drug-resistant epilepsy?: the 2016 Wartenberg lecture. Neurology 2016; 87:2483-2489.
2. Sørensen AT, Kokaia M. Novel approaches to epilepsy treatment. Epilepsia 2013; 54:1-10.
3. El-Shamayleh Y, Ni AM, Horwitz GD. Strategies for targeting primate neural circuits with viral vectors. J Neurophysiol 2016; 116:122-134.
4. Sudhakar V, Richardson RM. Gene therapy for neurodegenerative diseases. Neurotherapeutics 2019; 16:166-175.
5. Shoemaker LD, Kornblum HI. Neural stem cells (NSCs) and proteomics. Mol Cell Proteomics 2016; 15:344-354.
6. Bond AM, Ming Gl, Song H. Adult mammalian neural stem cells and neurogenesis: five decades later. Cell stem cell 2015; 17:385-395.
7. Nam H, Lee KH, Nam DH, Joo KM. Adult human neural stem cell therapeutics: current developmental status and prospect. World J Stem Cells 2015; 7:126-136.
8. Walker T, Huang J, Young K. Neural stem and progenitor cells in nervous system function and therapy. Stem Cells Int 2016; 2016: 1890568-1890570.
9. Burnight ER, Wiley LA, Mullins RF, Stone EM, Tucker BA. Gene therapy using stem cells. Cold Spring Harb Perspect Med 2015; 5:a017434.
10. Ladran I, Tran N, Topol A, Brennand KJ. Neural stem and progenitor cells in health and disease. Wiley Interdiscip Rev Syst Biol Med 2013; 5:701-715.
11. McLaren A. Ethical and social considerations of stem cell research. Nature 2001; 414:129-131.
12. Yu D, Silva GA. Stem cell sources and therapeutic approaches for central nervous system and neural retinal disorders. Neurosurg Focus 2008; 24:E11.
13. Liu S, Zhou J, Zhang X, Liu Y, Chen J, Hu B, et al. Strategies to optimize adult stem cell therapy for tissue regeneration. Int J Mol Sci 2016; 17:E982.
14. Arsenijevic Y, Villemure JG, Brunet JF, Bloch JJ, Déglon N, Kostic C, et al. Isolation of multipotent neural precursors residing in the cortex of the adult human brain. Exp Neurol 2001; 170:48-62.
15. Pagano SF, Impagnatiello F, Girelli M, Cova L, Grioni E, Onofri M, et al. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem cells 2000; 18:295-300.
16. Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004; 427:740-744.
17. Johansson CB, Svensson M, Wallstedt L, Janson AM, Frisén J. Neural stem cells in the adult human brain. Exp Cell Res 1999; 253:733-736.
18. Kukekov VG, Laywell ED, Suslov O, Davies K, Scheffler B, Thomas LB, et al. Multipotent stem/progenitor cells with similar properties arise from two neurogenic regions of adult human brain. Exp Neurol 1999; 156:333-344.
19. Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann IIG, Jiang L, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003; 9:439-447.
20. Ghasemi S, Aligholi H, Koulivand PH, Jafarian M, Ravandi HH, Ghadiri MK, et al. Generation of motor neurons from human amygdala-derived neural stem-like cells. Iran J Basic Med Sci 2018; 21:1155-1160.
21. Negah SS, Oliazadeh P, Jahan-Abad AJ, Eshaghabadi A, Samini F, Ghasemi S, Asghari A, Gorji A. Transplantation of human meningioma stem cells loaded on a self-assembling peptide nanoscaffold containing IKVAV improves traumatic brain injury in rats. Acta Biomater 2019; 92:132-144.
22. Jahan-Abad AJ, Negah SS, Ravandi HH, Ghasemi S, Borhani-Haghighi M, Stummer W, et al. Human neural stem/progenitor cells derived from epileptic human brain in a self-assembling peptide nanoscaffold improve traumatic brain injury in rats. Mol Neurobiol 2018; 55:9122-9138.
23. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther 2009; 17:767-777.
24. Wollebo HS, Woldemichaele B, White MK. Lentiviral transduction of neuronal cells.  Methods Mol Biol 2013; 1078:141-146.
25. Suh H, Zhou QG, Fernandez-Carasa I, Clemenson Jr GD, Pons-Espinal M, Marti M, et al. Long-term labeling of hippocampal neural stem cells by a lentiviral vector. Front Mol Neurosci 2018; 11:415-424.
26. Li M, Husic N, Lin Y, Christensen H, Malik I, McIver S, et al. Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods 2010; 189:56-64.
27. Wu P, Ye Y, Svendsen CN. Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors. Gene Ther 2002; 9:245-255.
28. Dhara SK, Gerwe BA, Majumder A, Dodla MC, Boyd NL, Machacek DW, et al. Genetic manipulation of neural progenitors derived from human embryonic stem cells. Tissue Eng Part A 2009; 15:3621-3634.
29. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. Science 1994; 263:802-805.
30. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272:263-267.
31. Okano H. Stem cell biology of the central nervous system. J Neurosci Res 2002; 69:698-707.
32. Gonzalez R, Hamblin MH, Lee JP. Neural stem cell transplantation and CNS diseases. CNS Neurol Disord Drug Targets 2016; 15:881-886.
33. Donde A, Wong PC, Chen LL. Challenges and advances in gene therapy approaches for neurodegenerative disorders. Curr Gene Ther 2017; 17:187-193.
34. Silva MC, Haggarty SJ. Human pluripotent stem cell–derived models and drug screening in CNS precision medicine. Ann N Y Acad Sci 2019; 1-39
35. Simonato M. Gene therapy for epilepsy. Epilepsy Behav 2014; 38:125-130.
36. Drew L. Gene therapy targets epilepsy. Nature 2018; 564:S10-S11.
37. Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, et al. Localized delivery of fibroblast growth factor–2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A 2009; 106:7191-7196.
38. Kanter-Schlifke I, Sørensen AT, Ledri M, Kuteeva E, Hökfelt T, Kokaia M. Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity. Neuroscience 2007; 150:984-992.
39. Theofilas P, Brar S, Stewart KA, Shen HY, Sandau US, Poulsen D, et al. Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. Epilepsia 2011; 52:589-601.
40. Woldbye DPD, Ängehagen M, Gøtzsche CR, Elbrønd-Bek H, Sørensen AT, Christiansen SH, et al. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 2010; 133:2778-2788.
41. Haberman RP, Criswell HE, Snowdy S, Ming Z, Breese GR, Samulski RJ, et al. Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol Ther 2002; 6:495-500.
42. Wang PC, Shan L. Essential elements to consider for MRI cell tracking studies with iron oxide-based labeling agents. J Basic Clin Med 2012; 1:1-6.
43. Mothe AJ, Kulbatski I, van Bendegem RL, Lee L, Kobayashi E, Keating A, et al. Analysis of green fluorescent protein expression in transgenic rats for tracking transplanted neural stem/progenitor cells. J Histochem Cytochem 2005; 53:1215-1226.
44. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018; 32:1529-1541.